Oppenheimer analyst Andreas Argyrides initiated coverage of Liquidia with a Perform rating and no price price target. Despite receiving tentative approval in November 2021, Liquidia’s lead product candidate for the treatment of pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease – YUTREPIA – has yet to cross the regulatory finish line, the analyst tells investors in a research note. Liquidia is bogged down by ongoing and “what feels like endless litigation” with United Therapeutics (UTHR) as YUTREPIA continues to face commercial uncertainty as to when it might come to market, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
- Biotech Alert: Searches spiking for these stocks today
- District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
- Liquidia says court denies motion for preliminary injunction filed by United Therapeutics
- Liquidia Technologies Enhances Executive Severance Benefits